Clinical Trials on Non-small Cell Lung Carcinoma in Germany

Total 1300 results

Novartis Pharmaceuticals

Terminated

Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-A (Canopy-A)

Non-Small Cell Lung Cancer

United States, Germany, Canada, France, Spain, Japan, Taiwan, Italy, Argentina, Austria, Poland, Russian Federation, United Kingdom, Korea, Republic of, Hong Kong, Thailand, Lebanon, Bulgaria, Greece, Israel, Slovenia, Switzerland, ... and more
ETOP IBCSG Partners Foundation

Completed

Afatinib in NSCLC With HER2 Mutation (NICHE)

NSCLC

Switzerland, Germany, Spain, Netherlands
GlaxoSmithKline

Terminated

GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer

Lung Cancer, Non-Small Cell

United States, Australia, Canada, Netherlands, Finland, Taiwan, Czechia, Estonia, Spain, Argentina, Belgium, France, Sweden, Germany, Israel, Italy, Korea, Republic of, Singapore, Ukraine, United Kingdom, Austria, Ireland, Thailand, C... and more
University Hospital, Essen

Recruiting

PET-guided Radiotherapy for Patients With Small Cell Lung Cancer. (PET-ART)

Small Cell Lung Carcinoma

Germany
Charite University, Berlin, Germany
ribosepharm GmbH

Unknown

Study to Determine the Efficacy of Bendamustin in Patients With Recurrent Small Cell Lung Cancer (SCLC)

Recurrent Small Cell Lung Cancer

Germany
Genentech, Inc.

Completed

Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab With and Without Pictilisib in Previously Untreated Advanced or Recurrent Non-small Cell Lung Cancer

Non-Small Cell Lung Cancer

United States, France, Hungary, Australia, Brazil, Canada, Spain, Germany, United Kingdom, Chile, Israel, Italy, Netherlands, Argentina, Ukraine, Russian Federation
Charite University, Berlin, Germany
Pfizer; Aventis Pharmaceuticals

Unknown

A Study for Small Cell Lung Cancer (SCLC) in Extensive Disease Stage

Small Cell Lung Cancer

Germany
GlaxoSmithKline
iTeos Therapeutics

Recruiting

A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer

Lung Cancer, Non-Small Cell

Finland, Italy, Netherlands, Spain, United States, Argentina, Belgium, Brazil, Germany, Greece, Hungary, Korea, Republic of, United Kingdom, Poland, France, Thailand, Japan, South Africa, Turkey, United Arab Emirates, Mexico, Port...
Universität des Saarlandes

Recruiting

Durvalumab With Consolidative Radiochemotherapy and Ablative Stereotactic Radiotherapy in Oligometastatic ES-SCLC

Extensive-stage Small-cell Lung Cancer

Germany
LMU Klinikum
Department of Internal Medicine V, Thoracic Oncology Centre Munich, LMU Munich... and other collaborators

Recruiting

Prospective Evaluation of Immunological, Molecular-genetic, Image-based and Microbial Analyzes to Characterize Tumor Response and Control in Patients With Inoperable Stage III NSCLC Treated With Chemoradiotherapy Followed by Consolidation Therapy With Durvalumab (PRECISION)

Oncology | NSCLC, Stage III | Chemoradiotherapy | Biomarker | Durvalumab

Germany
Eli Lilly and Company

Completed

A Study of Chemotherapy and Ramucirumab Versus Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer (NSCLC) Participants Who Received Prior First Line Platinum-based Chemotherapy

Non-Small Cell Lung Cancer

United States, Germany, Israel, Italy, Mexico, France, Poland, Romania, Spain, Taiwan, United Kingdom, Hungary, Austria, Argentina, Korea, Republic of, Greece, Turkey, India, Netherlands, Russian Federation, Canada, Norway, Sweden, Br... and more
Hoffmann-La Roche

Completed

A Study of Atezolizumab in Participants With Programmed Death - Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (BIRCH)

Non-Small Cell Lung Cancer

United States, Belgium, Hong Kong, Italy, Slovenia, Australia, Canada, Bulgaria, Germany, France, Georgia, Singapore, Spain, Bosnia and Herzegovina, Switzerland, Turkey, Japan, United Kingdom, Netherlands
Hoffmann-La Roche

Completed

A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer

Australia, China, Korea, Republic of, Denmark, Germany, Greece, Russian Federation, Hungary, France, New Zealand, Spain, Austria, Slovakia, United Kingdom, Malaysia, Lithuania, South Africa, Slovenia, Italy, Canada, Belgium, Poland, Czech Republic and more
Bristol-Myers Squibb

Withdrawn

An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer | Lung Cancer

Italy, Korea, Republic of, Turkey, Canada, Spain, Australia, Mexico, Taiwan, France, Germany, Switzerland, Greece, Japan, Austria, United States, Brazil, Czechia
Hoffmann-La Roche

Completed

A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer

Australia, China, Korea, Republic of, Denmark, Germany, Greece, Russian Federation, Hungary, France, Netherlands, New Zealand, Spain, Austria, Slovakia, United Kingdom, Malaysia, Belgium, Lithuania, South Africa, Slovenia, Italy, ... and more
Seagen Inc.
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of SEA-CD40 Given With Other Drugs in Cancers

Melanoma | Carcinoma, Non-Small- Cell Lung

United States, Canada, Spain, France, Germany, Sweden
Hoffmann-La Roche

Active, not recruiting

A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) (AcceleRET-Lung)

Neoplasms | Neoplasms by Histologic Type | Lung Diseases | Neoplasms by Site | Adenocarcinoma | Carcinoma | Neoplasms, Germ Cell and Embryonal | Head and Neck Neoplasms | Carcinoma, Non-Small-Cell Lung | Bronchial Diseases | Respiratory Tract Neoplasms | Thoracic Neoplasms | Carcinoma, Bronchogenic | Neoplasms, Nerve... and other conditions

Italy, Korea, Republic of, Australia, Spain, Argentina, Belgium, Brazil, France, Portugal, United Kingdom, United States, Japan, Mexico, Poland, Norway, Costa Rica, Switzerland, Netherlands, Germany, Sweden, Turkey, Ireland, Panama
Novartis Pharmaceuticals

Completed

LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib

Non-Small Cell Lung Cancer

United States, Spain, United Kingdom, Japan, Turkey, Belgium, Germany, Netherlands, Canada, Singapore, Switzerland, Israel, Russian Federation, Korea, Republic of, Hong Kong, Lebanon, Italy, France, Portugal, Ireland
University Hospital, Essen

Recruiting

Phase-II Trial of Induction Chemotherapy and Chemoradiotherapy Plus/Minus Durvalumab and Consolidation Immunotherapy in Patients With Resectable Stage III NSCLC. (ESPADURVA)

NSCLC, Stage III

Germany
Novartis Pharmaceuticals

Completed

LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer

Non-Small Cell Lung Cancer

Italy, Spain, Taiwan, Germany, Netherlands, Singapore, Austria, Japan, Australia, France, Russian Federation, Sweden, Thailand, Korea, Republic of, Lebanon, Norway, United Kingdom, China, India, Brazil, Turkey, Poland, Denmark, Greece, ... and more
Novartis Pharmaceuticals

Completed

A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat

Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma

United States, Spain, Taiwan, Germany, Netherlands, United Kingdom, Korea, Republic of
CNAO National Center of Oncological Hadrontherapy
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy; Fondazione IRCCS... and other collaborators

Recruiting

Immunotherapy and Carbon Ion Radiotherapy In Solid Cancers With Stable Disease (ICONIC)

Melanoma | Non Small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Urothelial Carcinoma

Italy, Germany
Bayer

Completed

A Study of a New Chemotherapy Agent in Combination With Cisplatin to Treat Small Cell Lung Cancer

Carcinoma, Small Cell

Germany
Gilead Sciences

Active, not recruiting

Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) (EVOKE-01)

Non-Small Cell Lung Cancer

United States, Belgium, Spain, United Kingdom, Australia, Japan, Italy, France, Israel, Netherlands, Puerto Rico, Portugal, Greece, Brazil, Poland, Canada, Austria, Germany, Mexico, Turkey
Pfizer

Completed

ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer (ARCHER 1009)

Non-Small Cell Lung Cancer

United States, Korea, Republic of, United Kingdom, Greece, Slovakia, France, Belgium, Ireland, Japan, Spain, China, Sweden, India, Hungary, Switzerland, Russian Federation, Germany, Mexico, Denmark, Austria, Finland, Poland, South Africa
Merck Sharp & Dohme LLC

Active, not recruiting

Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867)

Non-Small Cell Lung Cancer

Poland, United States, Argentina, Australia, Austria, Brazil, Canada, France, Germany, Hungary, Italy, Japan, Korea, Republic of, Netherlands, New Zealand, Norway, Romania, Russian Federation, Spain, Switzerland, Taiwan, Turkey, Ukr... and more
AstraZeneca

Completed

A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer (ARCTIC)

Non - Small Cell Lung Cancer NSCLC

United States, France, Germany, Italy, United Kingdom, Belgium, Poland, Romania, Taiwan, Thailand, Canada, Korea, Republic of, Czechia, Hungary, Japan, Russian Federation, Hong Kong, Spain, Netherlands, Greece, Australia, Serbia, Bu... and more
Central European Society for Anticancer Drug Research
University Hospital, Essen; University Hospital, Basel, Switzerland; Assign Data... and other collaborators

Completed

Central European Society for Anticancer Research (CESAR) Study of Paclitaxel Therapeutic Drug Monitoring (CEPAC-TDM)

Carcinoma, Non-Small-Cell Lung

Switzerland, Germany
University Hospital Heidelberg
Dietmar Hopp Stiftung

Recruiting

Predicting Response to Neoadjuvant ATEZOLIZUMAB Plus Carboplatin/Nab Paclitaxel in Resectable Non-squamous NSCLC (iReP)

NSCLC Stage IIIB | NSCLC Stage II | NSCLC, Stage IIIA

Germany
GlaxoSmithKline

Active, not recruiting

Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-Small Cell Lung Cancer Who Have Progressed on Prior Anti- Programmed Death-ligand 1 (PD-[L]1) Therapy and Chemotherapy (COSTAR Lung)

Lung Cancer, Non-Small Cell

Argentina, Korea, Republic of, Spain, Finland, Taiwan, Italy, Netherlands, Germany, Australia, Mexico, United States, Belgium, Canada, United Kingdom, Greece, Romania, Sweden, Russian Federation, Poland, France, Brazil, Japan, Thailand and more
Novartis Pharmaceuticals

Recruiting

Dabrafenib and/or Trametinib Rollover Study

Melanoma | Solid Tumor | High Grade Glioma | Non Small Cell Lung Cancer | Rare Cancers

Spain, Germany, United States, Argentina, Austria, Denmark, France, Hungary, Netherlands, China, Japan, Thailand
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Active, not recruiting

An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC) (CheckMate 227)

Non-Small Cell Lung Cancer

United States, Italy, Poland, Spain, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czechia, Finland, France, Germany, Greece, Hungary, Ireland, Israel, Japan, Korea, Republic of, Lebanon, Mexico, Netherlands and more
Taiho Oncology, Inc.

Recruiting

REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors) (REZILIENT3)

Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation

United States, Spain, Canada, Italy, Israel, Japan, United Kingdom, Korea, Republic of, Germany, France, Turkey, Belgium, Netherlands, Philippines, Poland, Singapore
iOMEDICO AG
Roche Pharma AG

Completed

Impact of eHealth Monitoring on Overall Survival in Patients With Metastatic NSCLC / Extensive-stage SCLC / Advanced TNBC Under First-line Treatment With Atezolizumab Plus Chemotherapy (CHAPLIN)

Extensive-stage Small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Advanced (Locally Advanced and Inoperable or Metastatic), PD-L1 IC-positive TNBC

Germany
WiSP Wissenschaftlicher Service Pharma GmbH
Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH

Suspended

Panitumumab Plus Pemetrexed and Cisplatin (PemCisP) Versus PemCis in the First-line Treatment of Patients With Non-small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

Germany
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008)

Carcinoma, Squamous Cell, Non-small-cell Lung

Poland, Korea, Republic of, United States, Argentina, Australia, Austria, Brazil, Canada, France, Germany, Japan, Mexico, New Zealand, Romania, Russian Federation, Spain, Taiwan, Turkey, Ukraine, United Kingdom
AstraZeneca

Completed

A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer

Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma

Spain, Poland, Hungary, Ukraine, Germany
Hoffmann-La Roche

Active, not recruiting

A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants (ALEX)

Non-Small Cell Lung Cancer

United States, Korea, Republic of, Canada, Taiwan, Australia, France, Hong Kong, Italy, Portugal, Spain, United Kingdom, Brazil, Poland, Guatemala, Singapore, Thailand, Serbia, Ukraine, Bosnia and Herzegovina, China, Costa Rica, E... and more
Michael Hopp
AstraZeneca

Recruiting

Efficacy and Safety of Standard of Care Plus Durvalumab in Patients With Limited Disease Small Cell Lung Cancer (DOLPHIN)

Small Cell Lung Cancer Limited Stage

Germany
Institut für Klinische Krebsforschung IKF GmbH...
AstraZeneca; Thoraxklinik-Heidelberg gGmbH

Recruiting

Thoracic Radiotherapy Plus Durvalumab in Elderly and/or Frail NSCLC Stage III Patients Unfit for Chemotherapy (TRADE-hypo)

NSCLC, Stage III

Germany
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Active, not recruiting

Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)

Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification | Lung Adenocarcinoma Stage IIIB/IV

Spain, Taiwan, United States, Korea, Republic of, Netherlands, Israel, Belgium, Italy, China, France, Germany, Japan, Poland, Austria, Switzerland
Boehringer Ingelheim

Completed

Nintedanib and Weekly Docetaxel in Lung Adenocarcinoma

Carcinoma, Non-Small-Cell Lung

France, Germany
Ariad Pharmaceuticals
Takeda

Active, not recruiting

A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (ALTA-2)

ALK-positive Advanced NSCLC

Korea, Republic of, United States, Spain, Taiwan, Canada, Hong Kong, China, Sweden, Australia, Italy, Japan, Germany, Netherlands, France, Austria
Amgen

Terminated

Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy

Cancer | Anemia | Non-Small Cell Lung Cancer | Lung Cancer

United States, Belgium, Italy, Poland, Switzerland, Canada, Germany, Russian Federation, China, Taiwan, United Kingdom, Hong Kong, Austria, Brazil, Israel, South Africa, Czechia, Greece, Spain, Netherlands, Bulgaria, Romania, Ireland, Puerto Rico and more
Transgene

Completed

Immunotherapy With TG4010 in Patients With Advanced Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

France, Germany, Hungary, Poland
Aktion Bronchialkarzinom e.V.
Roche Pharma AG

Completed

Inoperable Non-Squamous NSCLC Stage III/IV: A Randomised Phase II Study With Bevacizumab Plus Erlotinib Or Gemcitabine/Cisplatin Plus Bevacizumab (INNOVATIONS)

Carcinoma, Non-Small-Cell Lung

Germany
Novartis Pharmaceuticals

Terminated

Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations

Carcinoma, Non-Small-Cell Lung

Belgium, Germany, United States, Canada, France, Italy, Japan, Korea, Republic of, Spain
Takeda

Active, not recruiting

A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer (ALTA-3)

ALK+ Advanced NSCLC

Spain, China, Korea, Republic of, Taiwan, Hong Kong, Thailand, Italy, Romania, United States, Mexico, Croatia, Russian Federation, Argentina, Canada, Germany, France, Austria, Chile, Greece, Sweden
Novartis Pharmaceuticals

Completed

Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation (GeoMETry-III)

Carcinoma, Non-Small-Cell Lung

Belgium, Germany, Italy, France, Netherlands, Spain, Korea, Republic of, India, Brazil, Portugal
BioNTech SE

Active, not recruiting

Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411

Solid Tumor | Extensive-stage Small Cell Lung Cancer

United States, Spain, United Kingdom, Germany

Clinical Trials on Non-small Cell Lung Carcinoma in Germany

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uzbekistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations